Accuray Inc (ARAY): Fair Value Consensus

Symbol and logo of brand Accuray Inc (ARAY)

This Accuray Incorporated (ARAY) price chart illustrates the dynamics of a company whose sales depend on clinic funding and the implementation of radiosurgical innovations, with the current indicator standing at 13.98. Management is effectively expanding sales markets, although R&D costs are weighing on profits. A narrow profile in robotic therapy is complemented by steady earnings from software and technical maintenance.

Consensus Target: Accuray Inc. (ARAY) for 07/04/2022 - 11/11/2026
Original product of Accuray Inc.

The average target price from various experts neutralizes subjective deviations, determining the asset's fair value through the aggregation of market expectations. For Accuray Incorporated (ARAY), changes in the consensus price forecast reflect the balance between stable service revenue and the volatility of clinic capital expenditures, allowing investors to assess the business's resilience to customer budget constraints.

Competing companies

Analyst Consensus Forecast beigene.com (ONC)|Price Target Chart Halozyme HALO|Fair Value Consensus RVMD|Ascentage - Analyst Consensus Forecast|CGON - Analyst Consensus Forecast|URGN (UroGen Pharma Ltd.) - Consensus Target|Average Forecast Price bicara.com (BCAX)|PSNL (Personalis) - Analyst Consensus Forecast|Consensus Target Erasca Inc (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast Y-mAbs Corp (YMAB)|Price Target Chart Aura Biosciences, Inc. AURA|CADL: Broker Consensus Forecast|SELLAS Life Sciences Group Inc. - Analyst Consensus Forecast|Actuate Therapeutics Inc. (ACTU) - Consensus Target|CTOR: Analyst Consensus Forecast|Average Forecast Price TuHURA Biosciences (HURA)|Price Target Chart Protara Therapeutics|FATE: Fair Value Consensus|Consensus Target WHWK (Aadi Bioscience Inc)|TCRX (tscan.com) - Fair Value Consensus|Analyst Consensus Forecast CSBR (Champions Oncology, Inc.)|XBIT - Consensus Target|CVM: Consensus Target|OSTX - Analyst Consensus Forecast|Radiopharm Theranostics Limited (RADX) - Price Target Chart|Artiva Biotherapeutics - Fair Value Consensus|ANL (Adlai Nortye Ltd) - Analyst Consensus Forecast|Average Forecast Price Veru Corporation VERU|Analyst Consensus Forecast TPST|Analyst Consensus Forecast xiliotx.com (XLO)|Analyst Consensus Forecast RENB (Renovaro)|MURA - Consensus Target|Kairos Pharma Inc - Analyst Consensus Forecast|OnKure Therapeutics Inc (OKUR) - Consensus Target|GDTC (w2.cytomed.sg) - Consensus Target|Curis (CRIS) - Analyst Consensus Forecast|Price Target Chart Apollomics Inc.|THAR: Fair Value Consensus|Analyst Consensus Forecast ADVB|Analyst Consensus Forecast Genprex Inc (GNPX)|Calidi Biotherapeutics, Inc. - Consensus Target|Sunshine Biopharma Inc. (SBFM) - Average Forecast Price|XBIO: Consensus Target|Fair Value Consensus SLRX (Salarius Pharmaceuticals Inc)|PPBT: Analyst Consensus Forecast|AONC - Analyst Median Target|Price Target Chart BeiGene, Ltd.|Broker Consensus Forecast CKPT (checkpointtx.com)|Analyst Consensus Forecast ELEV|Consensus Target icadmed.com ICAD|Price Target Chart Ikena Oncology IKNA|Notable Labs Corp (NTBL) - Average Forecast Price|VIRX - Price Target Chart|Fair Value Consensus MOR (morphosys.com)|NAYA Biosciences Inc. (NAYA) - Price Target Chart|Forecast Levels Chart AAPGV (Ascentage Pharma Group International)